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Enterococcus faecalis Overcomes Foreign Body-Mediated Inflammation
To Establish Urinary Tract Infections
Pascale S. Guiton,a,b Thomas J. Hannan,c Bradley Ford,a,b,c Michael G. Caparon,a,b Scott J. Hultgrena,b
Department of Molecular Microbiology and Microbial Pathogenesis,a Center for Women’s Infectious Disease Research,b and Department of Pathology and Immunology,c
Washington University in St. Louis, Saint Louis, Missouri, USA
Urinary catheterization elicits major histological and immunological changes that render the bladder susceptible to microbial
invasion, colonization, and dissemination. However, it is not understood how catheters induce these changes, how these changes
act to promote infection, or whether they may have any protective benefit. In the present study, we examined how catheter-asso-
ciated inflammation impacts infection by Enterococcus faecalis, a leading cause of catheter-associated urinary tract infection
(CAUTI), a source of significant societal and clinical challenges. Using a recently optimized murine model of foreign body-asso-
ciated UTI, we found that the implanted catheter itself was the primary inducer of inflammation. In the absence of the silicone
tubing implant, E. faecalis induced only minimal inflammation and was rapidly cleared from the bladder. The catheter-induced
inflammation was only minimally altered by subsequent enterococcal infection and was not suppressed by inhibitors of the neu-
rogenic pathway and only partially by dexamethasone. Despite the robust inflammatory response induced by urinary implanta-
tion, E. faecalis produced biofilm and high bladder titers in these animals. Induction of inflammation in the absence of an im-
planted catheter failed to promote infection, suggesting that the presence of the catheter itself is essential for E. faecalis
persistence in the bladder. Immunosuppression prior to urinary catheterization enhanced E. faecalis colonization, suggesting
that implant-mediated inflammation contributes to the control of enterococcal infection. Thus, this study underscores the need
for novel strategies against CAUTIs that seek to reduce the deleterious effects of implant-mediated inflammation on bladder ho-
meostasis while maintaining an active immune response that effectively limits bacterial invaders.
Urinary catheterization is directly associated with 80% of hos-pital-acquired urinary tract infections (UTIs) (1). The inser-
tion and presence of indwelling urinary catheters disrupt the nor-
mal mechanical and host defenses of the urinary tract, allow
extracellular microbes access to the sterile environment of the
bladder by ascending through the catheter lumen or from the
urethral meatus along the catheter, and provide an additional sur-
face for biofilm formation and the establishment of antibiotic-
recalcitrant chronic or recurrent infections (2–9). Even in the ab-
sence of microbial colonization, urinary catheterization was
shown to be associatedwith histological and immunological alter-
ations in the bladder, including urothelial damage and exfoliation,
bladder wall edema, inflammatory cytokine production, immune
cell infiltration, and mucosal lesions of the bladders and kidneys
(7, 10–13) which can lead to bladder cancers (14, 15). However,
there remains a need to uncover molecular details and the func-
tional role of the catheter-induced host responses during bacterial
colonization and catheter-associated UTIs (CAUTIs).
We recently optimized a murine model of foreign body-asso-
ciated UTI to investigate the pathophysiology of enterococcal
CAUTIs, which account for 15 to 30% of CAUTIs (16). We dem-
onstrated that the transpeptidase enzymes sortase A and sortase C
and the endocarditis- and biofilm-associated pilus (Ebp) contrib-
ute to Enterococcus faecalis biofilm formation on the surface of
silicone implants in vivo, allowing for the establishment of persis-
tent cystitis and pyelonephritis in this murine model (17, 18).
Interestingly, this high and chronic enterococcal colonization oc-
curs in the face of a robust inflammatory response primarily
caused by the foreign body (18). However, from this study it was
unclear whether E. faecalis takes advantage of the host inflamma-
tory response for colonization and biofilm formation, as was
previously reported for uropathogenic Escherichia coli (UPEC)
(19) and other pathogens such as Salmonella enterica serovar
Typhimurium and nontypeable Haemophilus influenzae (20–
22), or if it employs other strategies to persist in the catheter-
inflamed bladder.
In the present report, we sought first to characterize the im-
mune response associated with urinary catheterization using ge-
netic knockout mouse strains and flow cytometry-based assays
and second to investigate the consequences of immune suppres-
sion and induction for the outcome of E. faecalis CAUTI. Our
findings indicate that the inflammation ensuing from bladder im-
plantation is primarily mediated by myeloid cells, in particular
neutrophils, which serve to control and limit E. faecalis infection.
This inflammatory response did not predispose the bladder to
infection by E. faecalis, since the induction of inflammation in the
absence of a foreign body did not promote infection. However,
not only is E. faecalis able to withstand this foreign body-induced
inflammatory response, but it depends on the catheter implant for
persistence via an unknown mechanism that more than likely in-
volves its ability to produce biofilms on the silicone tubing (18).
This study thus provides an explanation for the clinical observa-
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tions that E. faecalis is commonly recovered from patients with
foreign body-associated infections or under immunosuppressive
therapies and suggests that although immunosuppressive ap-
proaches for the management of CAUTIs may help limit the del-
eterious consequences of urinary catheterization for bladder biol-
ogy, they may inadvertently predispose patients to increased
bacterial colonization and dissemination leading to adverse side
effects and more severe infections.
MATERIALS AND METHODS
Bacterial strain and growth conditions. E. faecalis strain OG1RF, resis-
tant to rifampin and fusidic acid (23, 24), was used in this study. Unless
otherwise specified, experiments were performed using an overnight bac-
terial culture grown in brain heart infusion broth (BHI) (Becton, Dickin-
son, Franklin Lakes, NJ) from a single colony of OG1RF grown on BHI
agar plates supplemented with 25 g/ml of rifampin and 25 g/ml of
fusidic acid (BHIRF25). Liquid cultures were grown statically at 37°C for
18 h.
Inhibitors and chemicals. The drug treatments used in this study,
their relevantmodes of action, and references for dosage and effectiveness
are described in Table 1. Vehicles were saline or dimethyl sulfoxide
(DMSO) as indicated.
Mouse strains. Six- to 7-week-old female wild-type C57BL/6Ncrmice
purchased from the National Cancer Institute (NCI) were used in this
study. Experiments were performed following a 1-week adaptation in the
animal facility. All studies and procedures were approved by the Animal
Studies Committee at Washington University School of Medicine.
Animal implantation and infection. Animals were transurethrally
implanted and inoculated as previously described (18). Briefly, 7- to
8-week-old femalemice were anesthetized by inhalation of isoflurane and
implanted with a 4- to 5-mm length of platinum-cured silicone tubing.
Immediately following implantation, or at time of infection for nonim-
planted animals, 50 l of1 107 to 2 107 CFU of bacteria in phos-
phate-buffered saline (PBS) was introduced in the bladder lumen by
transurethral inoculation, when indicated.
Bladder weight determination and PPE. When indicated, bladders
were aseptically removed, bisected, and blotted dry. Bladders were placed
in preweighed Eppendorf tubes and weighed. Bladder weight (in grams)
was determined as the difference between bladder and Eppendorf tube
weight and that of the empty Eppendorf tube. Plasma protein extravasa-
tion (PPE) in the bladder was determined using the Evans blue technique
(25) in nonimplanted and implanted animals at 6 h after treatments with
the indicated chemicals listed in Table 1. Mice were anesthetized by inha-
lation of isoflurane, and 30 mg/kg of body weight Evans blue (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) was administered intravenously
(i.v.). Animals were sacrificed 15 min later by cervical dislocation. The
bladder was then excised, bisected, and blotted dry before weighing. Blad-
ders were then placed in 1 ml of 100% formamide (Sigma-Aldrich) and
incubated at 60°C for 24 h for Evans blue extraction. The extracted Evans
blue from each bladder was quantified by colorimetric measurement at
620 nm with an automated microplate reader. The dye content extrava-
sated in each bladder was determined from an Evans blue standard curve
and expressed as g/g of tissue.
Bacterial titer determination on implants and organs.Animals were
sacrificed at indicated time points by cervical dislocation after anesthesia
inhalation, and the bladders and kidneys were aseptically harvested. Sub-
sequently, the silicone implant was retrieved from the bladder when pres-
ent, placed in PBS, sonicated for 10 min, and then vortexed at maximum
speed for 3 min. The bladder and kidneys from each mouse were homog-
enized in PBS. Samples were serially diluted and plated onto BHI agar
plates containing rifampin. CFU were enumerated after 24 h of incuba-
tion at 37°C. In all cases, experiments were performed at least twice with
n 5 to 10 mice/condition/experiment.
Cytokine profiling. Bladder homogenates from nonimplanted and
implanted animals with or without bacterial infections were microcentri-
fuged at 14,000  g for 5 min, and supernatants were frozen at 80°C
until the time of the assay. Assays were carried out according to the man-
ufacturers’ protocols using the Bio-Plex Promouse cytokine 23-plex assay
kit from Bio-Rad Laboratories (Hercules, CA).
Histopathology. For histological analyses, bladders were fixed in
methacarn (60%methanol, 30% chloroform, and 10% glacial acetic acid)
or formalin for 1 to 2 h at room temperature and dehydrated in 70%
ethanol overnight at 4°C. They were then embedded in paraffin, sec-
tioned, and stained with hematoxylin and eosin (H/E) for light micros-
copy.
Flow cytometry. Single-cell bladder suspensions were made from
minced bladder tissues subjected to collagenase/DNase I digestion for 90
min at 37°C and thenpassed through a 40-mfilter, and cells werewashed
as described previously (26). Staining of surface markers was performed
in FcR block with fluorochrome-conjugated monoclonal antibodies
(MAbs). Cells were counterstained with propidium iodide (PI) prior to
flow cytometry, and only live (PI-low) cells were included in the analysis
(gating strategies are shown in Fig. S1 in the supplemental material). To
specifically characterize the immune infiltrates, specific combinations of
MAbs were chosen which distinguish granulocytes (CD11b Gr1hi
Ly6Ghi Ly6Clo), monocytes/macrophages (F4/80), dendritic cells
(CD11c), basophils (cKit FcεR1), eosinophils (SiglecF), mast cells
(cKit FcεR1),NK cells (NK1.1), T cells (CD3), andB cells (CD19).
All antibodies were from BD Pharmagen, Ebioscience, or Southern Bio-
tech. Activation status was determined using specific MAbs for major
histocompatibility complex class II (MHCII). Samples were acquired on a
FACSCalibur (BDBiosciences), anddatawere analyzed using FlowJo soft-
ware (version 7.6.4). The relative proportion of cellular infiltrates in each
bladder was calculated as a percentage of live cells.
Neutrophil depletion.Mice were rendered neutropenic as previously
described (26). Briefly, an anti-Ly6G MAb (1A8) from Bio X Cell (West
Lebanon, NH) was administered intraperitoneally (i.p.) on days 3 and 1
prior to implantation and bacterial challenge. Control mice received IgG
isotype control 2A3 (Bio X Cell) in a similar manner.
TABLE 1 List of inhibitors used in this study
Name Dosage/routea Mode of action Company/references




CP-99,994 dihydrochloride 5–10 mg/kg, i.p., i.v., s.c., 30 min and 3 h
postimplantation (when indicated)




CP-96,345 5–10 mg/kg, i.p., i.v., s.c., 30 min and 3 h
postimplantation (when indicated)
High-affinity NK1R antagonist Tocris Bioscience (79)
Aminoguanidine hydrochloride 200 mg/kg 1 h and 3 h postimplantation
(when indicated)
Irreversible inducible nitric oxide
synthase (iNOS) inhibitor
Tocris Bioscience (27)
Cyclophosphamide 150 mg/kg at time of infection Chemotherapeutic agent/prodrug Tocris Bioscience (33, 67)
a i.v., intravenously; s.c., subcutaneously.
Guiton et al.
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Statistical methods. Comparisons among groups were conducted by
the Mann-Whitney U test using GraphPad Prism (GraphPad software,
version 5). Values below the limit of detection (LOD) (40 CFU/ml for
organs and 20 CFU for implants) were assigned the appropriate LOD
value for statistical analyses. All tests were two-tailed, and a P value less
than 0.05 was considered significant. Colonization and infection were
defined as organs/implants with bacterial titers above LOD at 24 h postin-
fection (hpi).
RESULTS
Urinary catheterization induces severe edema and release of
proinflammatory cytokines. Examination ofmouse bladders fol-
lowing implantation of silicone tubing reveals severe edema (18).
However, the mechanisms of onset and progression of bladder
wall edema following urinary catheterization are poorly defined.
Thus, we investigated edema using bladder weight as a readout
followed by histological verification. The bladder weights of un-
infected mice were determined at 3, 6, 9, 12, 18, and 24 h postim-
plantation and compared to those of nonimplanted controls. The
bladders of implanted mice significantly increased in weight as
early as 3 h postimplantation (P 0.0011 by the Mann-Whitney
U test) compared to those of nonimplanted animals (normally 15
to 20 mg) and reached approximately 60 mg by 24 h (Fig. 1A).
Histological analysis of bladder tissue from implanted animals at
each time point depicts the gradual progression of bladder wall
edema over time, corroborating the significant increase in bladder
weight (Fig. 1C). The implant-induced edema correlates with
plasma protein extravasation (PPE) in the tissue as assessed by the
Evans blue extravasation assay performed 6 h postimplantation
(Fig. 1D). Significantly higher quantities of Evans blue per gramof
bladder tissue were extravasated and recovered from implanted
bladders following intravenous injection in the murine tail vein
(60 g), compared to approximately 30 g/g seen in nonim-
planted controls (P 0.0348). Urinary catheterization is also as-
sociated with the upregulation of several inflammatory cytokines
(18). Interleukins 1, 6, 12(p40), and 17 as well as granulocyte
colony-stimulating factor (G-CSF) and keratinocyte-derived
FIG 1 Bladder foreign body implantation induces edema and plasma protein extravasation. (A) Bladder weights of nonimplanted (control) and implanted ()
animals at the indicated times. (B) Bladder weights at 24 hpi of nonimplanted and implantedmice in the presence or absence of the E. faecalisOG1RF strain. (C)
H/E staining of bladder sections from nonimplanted and implanted animals at indicated time points observed under a light microscope at a magnification
of 10. (D) Plasma protein leakage in bladder tissue determined by Evans blue content at 6 hpi in nonimplanted animals treated with saline and implanted
animals treated with saline, dexamethasone (10mg/kg, i.p.), aminoguanidine (AG; 2 doses of 200mg/kg, i.p.), or CP-99,994 (2 doses of 5mg/kg, i.p.). All graphs
represent the mean of each data set from at least two independent experiments. Error bars show standard errors of the means. *, P 0.05; **, P 0.005; ***,
P 0.001; and ns, P	 0.05, by the Mann-Whitney U test.
Role of Inﬂammation during Enterococcal CAUTI
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chemokine (KC) are upregulated at least 2-fold in saline-treated
implanted animals over nonimplanted mock-infected controls
following urinary implantation (Fig. 2A).
Glucocorticoid treatment partially inhibits implant-in-
duced edema and inflammation. We used anti-inflammatory
and immunosuppressive agents in order to better understand the
mechanism by which the severe edema occurs in the bladder as a
result of urinary catheterization. We investigated the ability of (i)
dexamethasone, a well-characterized glucocorticoid and potent
anti-inflammatory agent; (ii) inhibitors of the neurogenic inflam-
matory pathway (NIP), including the neurokinin 1 receptor
(NK1R) antagonists CP-99,994 and CP-96,345 (27–30); or (iii)
aminoguanidine (AG), the irreversible inhibitor of inducible ni-
tric oxide synthase (iNOS) (31–33), to immunosuppress catheter-
induced edema and proinflammatory cytokines. Mice were intra-
peritoneally treated with each immunosuppressive agent 30 min
prior to implantation. Immunosuppression was evaluated based
on reduction in edema as determined by bladder weight, de-
creased plasma protein extravasation (PPE) by the Evans blue-
based assay, and reduced production of proinflammatory cyto-
kines.
Treatment with dexamethasone prevented the development of
bladder wall edema at 6 hpi (Fig. 1D) and delayed the increase in
bladder weight for up to 9 h postimplantation compared to saline-
treated controls (Fig. 2B). However, by 12 h postimplantation, the
bladders of dexamethasone-treated animals were as edematous
and inflamed as were saline-treated implanted controls (Fig. 2C).
Supplemental dosages of dexamethasone administered 30 min
prior to implantation and at 9 h postimplantation did not prevent
edema at 24 h postimplantation (data not shown). Dexametha-
sone also significantly decreased interleukins 1 and 12(p40) as
well as G-CSF and KC in implanted animals compared to saline-
treated implanted controls at 24 h postimplantation (Fig. 2A). In
contrast, known inhibitors of the NIP (Fig. 1D), including the
specific neurokinin 1 receptor (NK1R) antagonist CP-99,994 or
aminoguanidine (AG), the irreversible inhibitor of inducible ni-
tric oxide synthase (iNOS) (31–33), resulted in no reduction in
bladder weights, and vascular permeability was observed in im-
FIG 2 Dexamethasone treatment decreases cytokine production and delays onset of bladder edema. (A) Graph represents bladder cytokines with at least 2-fold
differential expression relative to uninfected nonimplanted animals at 24 hpi for nonimplanted and saline- or dexamethasone-treated implanted animals with or
without OG1RF from at least two independent experiments (n 2 to 3mice/condition/experiment). Error bars standard errors of themeans. *, P 0.05, and
**, P 0.005, by the Mann-Whitney U test. ns, not significant (P	 0.05). (B) Bladder weights of female C57BL/6Ncr mice at the indicated time points treated
with saline or dexamethasone (10 mg/kg, i.p.) 30 min prior to implantation. White bars from the same data set represent weights of nonimplanted animals’
bladders. The experiment was done at least twice with n  5 mice/experiment/time point, except at 12 and 18 h (experiment performed once). Error bar 
standard error of the mean. **, P 0.005, and ***, P 0.001, by the Mann-Whitney U test. (C) H/E staining of bladder sections obtained at the indicated time
points from nonimplanted and implanted animals treated with saline or dexamethasone (10 mg/kg, i.p.) observed under a light microscope at a magnification
of40.
Guiton et al.
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planted animals. Similar findings were obtained with CP-96,345
(data not shown). Thus, NK1R-induced neurogenic inflamma-
tion does not appear to be a major contributor to the onset of
bladder wall edema and vascular permeability following urinary
implantation in mice. These data argue that activation of gluco-
corticoid-sensitive immune pathways contributes to the immedi-
ate inflammatory response following urinary implantation but
that dexamethasone-insensitive pathways, not related to the NIP,
dominate after 6 to 9 h postinfection.
Urinary implantation leads the specific recruitment of my-
eloid-derived cells in the murine bladder. Very little is known
about the cellular constituents of the immune response to urinary
catheterization aside from histological analyses of bladder tissues
(7, 13, 18). In order to establish the functional role of implant-
mediated inflammation, we investigated the cellular nature of im-
mune cells involved in the bladder immunological responses to
the silicone implant. We performed flow cytometric analysis of
bladder single cell suspensions in nonimplanted and implanted
animals at 24 h postimplantation using antibodies raised against
specific immune surface markers. These experiments reveal that
CD11b myeloid cells account for approximately 30% of the
live cell population in implanted animals compared to 10% in
nonimplanted controls at 24 h postimplantation (P  0.0001)
(Fig. 3A). No significant difference was observed in lymphocyte
(CD3CD19) numbers in the presence or absence of implant at
24 hpi (Fig. 3A). Specific markers were used to further specify the
myeloid cells. Nonactivated (CD11b F4/80 MHCII) and ac-
tivated (CD11b F4/80MHCII)macrophages are present with
FIG3 Neutrophils are important cellular infiltrates during enterococcal CAUTI. Cellular infiltrates fromnonimplanted animals (white bars), implanted animals
(black bars), or animals implanted and infected with E. faecalis OG1RF (gray bars) at 24 hpi derived from flow cytometry analysis. Nonactivated and activated
macrophages (CD11b F4/80MHCII and CD11b F4/80MHCII, respectively), neutrophils (CD11bGr1hi Ly6Ghi Ly6Clo), eosinophils (SiglecF), and
basophils (cKit FcεR1). Graphs represent the means derived from at least two independent experiments with n  3 to 5/experiment/condition. Error bars
represent standard errors of the means. *, P 0.05; **, P 0.005; and ***, P 0.0005, by the Mann-Whitney U test. ns, not significant (P	 0.05).
Role of Inﬂammation during Enterococcal CAUTI
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increases of approximately 12- and 2-fold, respectively, over
nonimplanted controls (Fig. 3B). Neutrophils (CD11b Gr1hi
Ly6Ghi Ly6Clo) are the most abundant immune cells recruited in
response to urinary implantation, accounting for approximately
8% of live cells compared to less than 0.05% in nonimplanted
controls (Fig. 3B). Further flow cytometric studies using an anti-
body raised against the neutrophil-specific receptor NB1 (also
known as CD177) (34) corroborate the above findings that neu-
trophils are the major immune infiltrates in implanted murine
bladders (data not shown). In addition, there was a significant
increase in basophils (cKit FcεR1) and eosinophils (SiglecF)
in the bladder of implanted animals, representing 5.6 and 4.2%,
respectively, of the live population (Fig. 3B). There was no statis-
tically significant change in the number of dendritic cells
(CD11bCD11cMHCII/) ormast cells (cKit FcεRI) pres-
ent in implanted animals compared to nonimplanted controls
(data not shown). Dexamethasone treatment prior to implanta-
tion significantly reduced immune cell recruitment at 24 hpi in
noninfected animals (data not shown).
Role of foreign body-induced bladder inflammation in E.
faecalisCAUTI.We investigated the role of the implant-mediated
edema and inflammation in promoting or altering the outcome of
enterococcal infections. In a murine model of cystitis, E. faecalis
inducesminimal inflammation and is rapidly eliminated from the
bladder (35). However, with the introduction of silicone tubing
implants into the bladder, E. faecalis becomes adept at causing
CAUTI despite the edema and the robust inflammatory response
induced by the catheter (36). Thus, we investigated whether E.
faecalis virulence was altered in animals preimplanted 24 h before
infection to determine the effect of a preexisting catheter-induced
inflammatory response on the outcome of infection. Animals that
were implanted and simultaneously infected served as a control.
Bacterial titers from the implant and organs were then analyzed
and compared. As shown in Fig. 4A, E. faecalis colonizes the im-
plants and organs of the two groups to similar levels, indicating
that preexisting implant-induced bladder inflammation does not
enhance or prevent enterococcal colonization.
To assess whether any inflammation predisposes the bladder to
E. faecalis infection in the absence of a foreign body, murine hem-
orrhagic cystitis was induced via treatment with cyclophospha-
mide (CYP) (150 kg/mg, intraperitoneally [i.p.]). CYP-induced
cystitis is a well-characterized model of bladder inflammation.
Even though CYP- and catheter-induced inflammatory responses
are not equivalent, they share some important commonalities de-
picted in Fig. 4B, such as bladder wall edema, mucosal damage,
and host immune cell infiltration (31, 32, 37, 38). When intro-
duced in nonimplanted CYP-treated animals, E. faecalis is rapidly
cleared from the urinary tract, similarly to saline-treated nonim-
planted controls at 6 hpi (Fig. 4C). By 24 hpi, bacteria are recov-
ered at very low levels (102 to 103 CFU/ml in organs) from both
experimental groups compared to implanted animals, whose or-
gans remain colonized at very high titers (105 to 106 CFU/ml; data
not shown). These findings suggest that the inflammatory state of
the bladder is not sufficient to promote E. faecalis infection of the
urinary tract in the absence of a foreign body.
Similarly to uninfected implanted animals, CD11b myeloid
cells comprise the predominant cellular infiltrates at 24 h in im-
planted animals with E. faecalis infection (Fig. 3A). However,
CD11bmyeloid cells account for approximately 40% of live cell
populations in CAUTI animals, significantly higher than in im-
FIG 4 Implant-induced inflammation is not sufficient for enterococcal urinary tract colonization. (A) CFU enumeration at 24 hpi of OG1RF from implants and
homogenized bladders and kidneys of animals preimplanted (Pre-imp) 24 h before or implanted (imp) on the day of bacterial challenge. (B) H/E staining of
bladder sections of 6-h cyclophosphamide (CYP)-treated or implanted mice observed under a light microscope (magnification, 20). The experiment was
performed in duplicate with n 3 to 5/group. (C) Graph represents OG1RF titers at 6 hpi from retrieved implants and homogenized bladders and kidneys from
nonimplanted CYP- or saline-treated and implanted (Imp) animals. For panels A and C, the horizontal bars indicate the median of each data set. Two
independent experiments performed with n 5 to 10/condition/experiment. *, P 0.05, and **, P 0.005, by the Mann-Whitney U test. ns, not significant.
Guiton et al.
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planted controls in the absence of E. faecalis (P  0.005). This
increase inmyeloid cells in the presence of E. faecalis is mainly due
to a 2-fold increase in the recruitment of neutrophils compared to
mock-infected implanted controls (P  0.001) (Fig. 3B). Similar
numbers of macrophages, basophils, and eosinophils are present
in the bladders of implanted animals whether or not E. faecalis is
present (Fig. 3B), indicating that recruitment and activation of
these immune cells occur specifically in response to the silicone
implant. Together, these results indicate that while the silicone
implant elicits the specific recruitment ofmyeloid infiltrates in the
bladder, only neutrophil recruitment is enhanced during entero-
coccal CAUTI.
Neutrophil recruitment contributes to antienterococcal re-
sponses.Having identified neutrophils as themajor immune cells
recruited in response to E. faecalis infection in the urinary tract of
implanted animals (Fig. 3B), we assessed their contribution to the
inflammatory response duringE. faecalis infection. For neutrophil
depletion, each mouse was rendered neutropenic following anti-
Ly6G (MAb clone 1A8) treatment administered first i.p. 3 days
and then 1 day prior to implantation and bacterial challenge (26).
At 24 hpi, there were approximately 1- and 1.5-log increases in
CFU recovered from implants and bladders of neutrophil-de-
pleted animals, respectively, compared to isotype-control anti-
body-treated implanted animals (P 0.05 in all cases) (Fig. 5A).
There was also a statistically significant0.5-log difference in the
kidney titers between the two groups. Notably, the bladders from
these neutropenic animals were as enlarged as were those from
their littermate controls in the absence and presence of bacterial
infections, indicating that neutrophils are not major contributors
to the pathway leading to vascular permeability following urinary
catheterization in mice. Together, these findings indicate that
neutrophils are dispensable for implant-induced edema but are
critical for controlling enterococcal colonization of the urinary
tract during CAUTI.
Glucocorticoid treatment significantly increases E. faecalis
urovirulence at 6 hpi. The effects of dexamethasone-induced im-
munosuppression on enterococcal virulence in implanted ani-
mals were assessed at 6 hpi and 24 hpi. As shown in Fig. 5B, en-
terococcal titers were 10-fold higher (P  0.031) on implants
recovered from dexamethasone-treated animals than on those
from saline-treated implanted controls at 6 hpi. No significant
difference in bacterial titers was observed in the bladder and kid-
neys between the two groups. By 24 hpi, E. faecalis recoveries from
implants were similar in dexamethasone- and saline-treated ani-
mals (Fig. 5B). Enterococcal infection in dexamethasone-treated
animals causes a significant increase in the production of proin-
flammatory cytokines, including interleukin-6 (IL-6), which was
similar to that in saline-treated infected animals, as shown in Fig.
2A. These data suggest that although dexamethasone did not af-
fect the ultimate production of many proinflammatory cytokines
in the bladder consequent to CAUTI, other dexamethasone-sen-
sitive pathways, such as immune cell activation and recruitment,
contribute to bacterial clearance in this model.
DISCUSSION
E. faecalis is amajor cause of nosocomial infections and an impor-
tant etiological agent of CAUTI. During CAUTIs, E. faecalis takes
advantage of the presence of the foreign body within the bladder
to produce biofilms and establish persistent infections in the uri-
nary tract. This infection occurs in the face of a robust immune
response, which is induced in mice as well as in patients primarily
in response to the presence of the foreign body within the bladder.
The murine model of foreign body-associated UTI recently opti-
mized for the study of enterococcal CAUTI and used in the pres-
ent study helps unravel critical aspects of the interplay between
inflammation and enterococcal colonization, providing new de-
tails of the molecular mechanisms leading to the foreign body-
mediated inflammatory response and its role in the outcome of E.
faecalis infection. We specifically showed that while induction of
inflammation in the murine bladder either by implantation or
chemically in the absence of implants is not sufficient to prevent or
promote E. faecalis infection, partial immunosuppression with
dexamethasone or neutrophil depletion prior to urinary implan-
tation and bacterial challenge enhances enterococcal colonization
of the implants and the urinary tract, suggesting that the immune
response in the implanted bladder does not favor enterococcal
infection but is simply ineffective at clearing the infection in our
murine model of CAUTI.
The bladder responses to urinary catheterization are character-
FIG 5 Neutrophil depletion and dexamethasone treatment enhances entero-
coccal CAUTI. (A) Graph represents OG1RF titers at 24 hpi on implants and
homogenized bladders and kidneys of implanted isotype IgG control (Iso-
type)- and anti-Ly6G (
-Ly6G)-treated mice. (B) Graph represents OG1RF
titers at 6 and 24 hpi from retrieved implants and homogenized bladders and
kidneys from saline- or dexamethasone-treated implantedmice. The horizon-
tal bars indicate the median of each data set from two independent experi-
ments with n  5 to 10/condition/experiment. The horizontal dashed lines
represent the limit of detection (lod). *, P  0.05, and **, P  0.005, by the
Mann-Whitney U test.
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ized by severe uroepithelial damage and exfoliation; the onset of
bladderwall edema from increased vascular permeability; the pro-
duction of proinflammatory cytokines IL-6, G-CSF, and KC, as
previously reported (18); and the recruitment of myeloid-derived
cells, particularly neutrophils. Neutrophils are the primary re-
sponders in implanted bladders followed by macrophages, baso-
phils, and some eosinophils. As previously reported (18), infec-
tion with E. faecalis increases the above cytokines and induces the
secretion of IL-1 and IL-12(p40). Here, we also report the induc-
tion of IL-17 following E. faecalis infection, which was signifi-
cantly upregulated and showed at least a 2-fold increase over non-
implanted uninfected controls. This cytokine was not previously
reported because it did not meet the 2-fold-change arbitrary re-
quirement specified above, even though we observed the statisti-
cally significant increase in the bladder following infection of im-
planted animals with E. faecalis (data not shown). Furthermore,
the neutrophil populations increased approximately 5-fold in the
presence of E. faecalis in implanted animals compared to im-
planted animals without bacterial challenge.
All the above immune characteristics, from edema to neutro-
philia, are associated with activation of the neurogenic inflamma-
tory pathway in various experimental models of cystitis, including
cyclophosphamide-induced hemorrhagic cystitis (39). This is an
inflammatory response triggered by the release of proinflamma-
tory neuropeptides and activation of surface receptors, including
NK1R, on the surface of sensory neurons (40). However, our data
indicate that the NK1R-mediated neurogenic inflammatory re-
sponse is not a major contributor of implant-induced cystitis in
mice since treatment with specific NK1R antagonists and iNOS
inhibitors did not prevent plasma protein leakage and edema as
was previously shown in cystitis or other experimental models
involving activation of the neurogenic pathway (32, 41, 42). Al-
though the contributions of other factors involved in the neuro-
genic inflammatory response, including mast cells, bradykinins,
and NK2 receptors, need to be assessed, identifying the effects of
urinary implantation on factors involved in vascular permeability,
such as calcium channels, calveolin, RhoGTPases, sphingosine ki-
nases (SPHK1), and protein tyrosine phosphatases (SHP2) (43),
may shed light on themechanisms underlying the onset of bladder
wall edema following catheterization.
In contrast to studies with specific inhibitors of the neurogenic
inflammatory response, glucocorticoid treatment delays the onset
of implant-associated edema and vascular permeability and par-
tially decreases cytokine production and cellular recruitment fol-
lowing urinary catheterization at 24 h posttreatment. Given that
the effects of dexamethasone on cytokine production persist up to
24 hposttreatment, it is very likely that the cytokines reported here
will also be suppressed at early stages (6 h posttreatment). To-
gether, these findings implicate glucocorticoid-responsive inflam-
matory pathways in the immune response during the early stages
of urinary implantation. While previous reports have shown that
synthetic glucocorticoids, such as dexamethasone and prednicar-
bate, inhibit neurogenic vascular permeability in the respiratory
tract of rodents and human forearm skin (44–52), the inhibitory
effects of glucocorticoids on this pathway remain questionable, as
other such compounds, including hydrocortisone and beta-
methasone, have been shown to have no effects or even to induce
this response in airways of rats (53, 54). Synthetic glucocorticoids,
including dexamethasone, are among the most effective anti-in-
flammatory agents used to date for the treatment of chronic in-
flammatory diseases (55). They are both anti-inflammatory and
immunosuppressive molecules whose mechanisms of action in-
volve in part transcriptional regulation via interaction and activa-
tion of glucocorticoid receptors (GR) in the host cytoplasm aswell
as posttranscriptional and -translational regulation of a myriad of
genes encoding proteins for cellular and immune processes (55,
56). Glucocorticoids are known inhibitors of inflammatory pro-
cesses mediated by interleukins (1, 2, 6, and 8) and other proin-
flammatory cytokines such as granulocyte-macrophage colony-
stimulating factor (GM-CSF) and tumor necrosis factor alpha
(TNF-
), phospholipase A2, and iNOS. The unresponsiveness to
dexamethasone observed in the later stages of urinary implanta-
tion has previously been reported in patients suffering from other
inflammatory diseases (57), including asthma (58), inclusion
body myositis (IBM) (59), and nephrotic syndrome (NS) in chil-
dren (60). In the case of the implanted bladders, glucocorticoid
refractoriness could be attributed to the ongoing exposure to the
foreign body (61), the high levels of neutrophils in the bladder
which have been previously associated with corticosteroid-resis-
tant asthma (61), a significant reduction in glucocorticoid recep-
tors (62) due to increased urothelial exfoliation, or other cellular
and immunological pathways that can circumvent the effects of
dexamethasone (61). These may include an increased expression
of the dominant negative form of the glucocorticoid receptors
(GR) on immune cells such as neutrophils and macrophages,
rendering them insensitive to dexamethasone treatment (63, 64);
upregulation of certain cytokines, including IL-2, IL-4, and IL-13;
or that from activation of the mitogen-activated protein kinase
(MAPK) signaling pathways (61). Notably, the suppression of the
early phase of implant-mediated cystitis following glucocorticoid
treatment or iNOS inhibition (see Fig. S3 in the supplemental
material) led to a significant increase in enterococcal implant col-
onization, indicating that by reducing the inflammatory re-
sponses, these treatments favor E. faecalis survival in the im-
planted bladder. Remarkably, by 24 h postinfection, enterococcal
infection in dexamethasone-treated animals induces an immune
response similar to that elicited in implanted and infected saline-
treated controls. At this later time point, no difference in bacterial
colonization in glucocorticoid-treated animals relative to un-
treated controls is observed. Thus, the immune response, while
detrimental to E. faecalis colonization, fails to completely clear
enterococcal infection. Further, these findings suggest that E.
faecalis possesses immune evasion mechanisms that allow its sur-
vival in the face of this glucocorticoid-resistant immune response
and that implant-mediated bladder inflammation, as in the case of
preimplanted animals, did not alter the outcome of infection. The
acute inflammatory response induced by the implant may even
alter or impair the host response to bacteria, as was demonstrated
for Enterococcus faecium peritonitis following treatment with tur-
pentine or casein prior to bacterial challenge (65).
E. faecalis colonization is also significantly increased in the
bladders of neutropenic mice following urinary implantation,
corroborating previous reports that neutrophils are important
mediators of the antienterococcal host response in humans and
other animal models of infections (66–69). Previous studies dem-
onstrated that E. faecalis and E. faecium isolated from saliva and
root canals are efficiently killed by neutrophils recruited to the site
of infection (70) and that TLR-2 is involved in the immune re-
sponse against E. faecium (71). However, the immune defense
during E. faecalis infections of the urinary tract at 24 hpi occurs in
Guiton et al.




arch 31, 2014 by W







a TLR-2- and IL-6-independent manner, as infection of im-
planted animals deficient in these immune modulators did not
alter the outcome of infection (see Fig. S2 in the supplemental
material). Further research is required to establish the molecular
mechanisms underlying the role of neutrophils during E. faecalis
infection. We have recently adapted an in vitro system to grow
biofilms on silicone tubing in filtered human urine under fluid
flow (72). However, unlike uropathogenic E. coli, E. faecalis failed
to produce biofilms under these conditions, even with the addi-
tion of extra carbon sources, such as glucose (data not shown).
Despite the absence of an in vitro system to study E. faecalis cath-
eter colonization, our in vivo findings strongly support the critical
role of neutrophils in delaying and controllingE. faecalis infection.
Uncovering the contribution of macrophages and other immune
cells, the Toll-like receptors, IL-8, and G-CSF signaling pathways
in the host immune response to enterococcal CAUTI will provide
more insights into the host response to these infections.
Despite the role of neutrophils in controlling E. faecalis infec-
tion, this bacterium is still able to colonize the urinary tract of
implanted immunocompetentmice, implying the presence of po-
tential mechanisms to help E. faecalis avoid and/or resist neutro-
phil killing. Recent studies have demonstrated that the cell wall-
anchored pheromone-inducible aggregation substance (AS) and
the enterococcal polysaccharide antigen (Epa) in E. faecalis are
involved in resistance to neutrophil-mediated killing (73–75).
However, the E. faecalis OG1RF strain used in the present study
does not bear AS, arguing for alternative mechanisms of immune
evasion, such as the downregulation of integrin 4 expression on
the surface of neutrophils (76); alteration of the neutrophil prop-
erties rendering them nonresponsive to bacterial infections, as is
the case during enterococcal sepsis in thermally injured patients
and mice (66, 68, 69); and survival within immune cells such as
macrophages and biofilm formation,which arewell-characterized
virulence attributes of enterococci (18, 77–89). Together, these
findings indicate that the inflammatory response to the urinary
implant is deleterious to E. faecalis but is inefficient at controlling
bacterial proliferation and colonization over time. Furthermore,
this report is in accord with epidemiological reports of severe en-
terococcal infections increasingly occurring in immunosup-
pressed and immunocompromised patients (90–93).
In addition to promoting persistent enterococcal cystitis, the
presence of the silicone implants in the bladder allows E. faecalis to
gradually and successfully ascend to the kidneys and establish re-
nal colonization in implanted animals. The onset of acute pyelo-
nephritis has been described in postmortem studies of the elderly
with indwelling catheters at the time of death (94). In the clinical
setting, the removal of infected indwelling urinary catheters is one
of the most effective methods used to resolve bacteriuria and
CAUTIs (3, 95). However, removing the indwelling medical de-
vice, even combined with a long course of antibiotic treatment
(95), may not be sufficient for complete resolution of the infec-
tion, especially with the rise in antibiotic resistance observed in
nosocomial settings (96). In addition, implant removal upon in-
fection in other device-associated infections like prosthetic valve
endocarditis is not in itself efficacious (97–99) and thus may not
be a suitable therapeutic approach in all instances. Understanding
the constituents of the pathophysiology of CAUTIs, namely, bio-
film formation and host immune response to urinary catheters,
may lead to the development of novel preventative and therapeu-
tic strategies that limit the damage to the uroepithelium while
enhancing effective immune responses to bacterial infections.
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